Dr William Sikov was talking about subtype, genetic subtype, and the response to either bevacizumab neoadjuvant therapy or carboplatin. Complex, a little bit complex, but there seemed to be a signal in some genetic subtypes influencing bevacizumab but not carboplatin. What did you make of all that?

I think that if I remember his data carboplatin was beneficial in terms of pathological complete response in tumours that were basal-like and non-basal-like also, all of them being triple negative breast cancer, right? The effect of bevacizumab, again I don’t know what to make of that. Bevacizumab improved pathological complete response in basal but reduced pathological complete responses in a very small group of non-basal which altogether was about 13% of the total. I don’t know what to make of that, bevacizumab is not being used so I don’t know whether that… That doesn’t do anything to me in terms of use of bevacizumab but it’s one more body of data suggesting that some patients with triple negative breast cancer, in some patients we may consider the addition of carboplatin.

And this might be based on genetic subtype?

Well, what his data suggests is no, it’s just based on clinical information. Triple negative.

So if you’re using carboplatin that’s not important?

Yes, triple negative. Based on that study, again, he saw the benefit on basal-like and non-basal-like, all triple negative which is a clinical definition.